[
  {
    "ts": null,
    "headline": "Eli Lilly Builds $1.5 Billion Pill Inventory",
    "summary": "Inventory jumps ahead of Q2 nod",
    "url": "https://finnhub.io/api/news?id=6078f3264f136e9a992249a3cfac1ce731b909e6ecc7efbc8729dde24ac9d414",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771005556,
      "headline": "Eli Lilly Builds $1.5 Billion Pill Inventory",
      "id": 139088026,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Inventory jumps ahead of Q2 nod",
      "url": "https://finnhub.io/api/news?id=6078f3264f136e9a992249a3cfac1ce731b909e6ecc7efbc8729dde24ac9d414"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Builds Orforglipron Inventory Ahead of FDA Review",
    "summary": "Drugmaker increases pre-launch stockpile as oral GLP-1 review approaches.",
    "url": "https://finnhub.io/api/news?id=4f2d9b734ac55ad462d7123a25b42e6c811b4da45ffb6cac4ab33b3ae4b0aa7e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771003444,
      "headline": "Eli Lilly Builds Orforglipron Inventory Ahead of FDA Review",
      "id": 139086539,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Drugmaker increases pre-launch stockpile as oral GLP-1 review approaches.",
      "url": "https://finnhub.io/api/news?id=4f2d9b734ac55ad462d7123a25b42e6c811b4da45ffb6cac4ab33b3ae4b0aa7e"
    }
  },
  {
    "ts": null,
    "headline": "Did Eli Lilly Just Make a Deal for Its Next Blockbuster Drug?",
    "summary": "Eli Lilly announced an acquisition of an innovative new autoimmune drug.",
    "url": "https://finnhub.io/api/news?id=21b1175e98601e8fccff0817bdbff0d4f773ab6e18677644b7a5686c6ff41f0a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770996900,
      "headline": "Did Eli Lilly Just Make a Deal for Its Next Blockbuster Drug?",
      "id": 139084994,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly announced an acquisition of an innovative new autoimmune drug.",
      "url": "https://finnhub.io/api/news?id=21b1175e98601e8fccff0817bdbff0d4f773ab6e18677644b7a5686c6ff41f0a"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Gets Upgraded to Buy From Hold by Freedom Capital",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best medical research stocks to buy according to hedge funds. On February 10, Eli Lilly and Company (NYSE:LLY) was upgraded to Buy from Hold by Freedom Capital, with the firm raising the price target on the stock to $1,200 from $1,050. The rating update came after […]",
    "url": "https://finnhub.io/api/news?id=987c8c718c064db87c630d2e9130ebbb463d4f5dc2c50e9bc141b6860496af41",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770994648,
      "headline": "Eli Lilly and Company (LLY) Gets Upgraded to Buy From Hold by Freedom Capital",
      "id": 139084995,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best medical research stocks to buy according to hedge funds. On February 10, Eli Lilly and Company (NYSE:LLY) was upgraded to Buy from Hold by Freedom Capital, with the firm raising the price target on the stock to $1,200 from $1,050. The rating update came after […]",
      "url": "https://finnhub.io/api/news?id=987c8c718c064db87c630d2e9130ebbb463d4f5dc2c50e9bc141b6860496af41"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Retains Buy Rating on Strong 2026 Outlook",
    "summary": "Eli Lilly & Company (NYSE:LLY) ranks among the best high growth high margin stocks to buy now. Deutsche Bank retained its Buy rating and $1,200 price target for Eli Lilly & Company (NYSE:LLY) on February 4, citing the pharmaceutical giant’s strong fiscal year 2026 projections. Eli Lilly & Company (NYSE:LLY) posted revenues of around $19.3 […]",
    "url": "https://finnhub.io/api/news?id=9481a9538043ccb3769c20b0b3456e68216c513c06ba921a58de370e902b0f1b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770994484,
      "headline": "Eli Lilly (LLY) Retains Buy Rating on Strong 2026 Outlook",
      "id": 139084996,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly & Company (NYSE:LLY) ranks among the best high growth high margin stocks to buy now. Deutsche Bank retained its Buy rating and $1,200 price target for Eli Lilly & Company (NYSE:LLY) on February 4, citing the pharmaceutical giant’s strong fiscal year 2026 projections. Eli Lilly & Company (NYSE:LLY) posted revenues of around $19.3 […]",
      "url": "https://finnhub.io/api/news?id=9481a9538043ccb3769c20b0b3456e68216c513c06ba921a58de370e902b0f1b"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly (LLY) is a Top Momentum Stock for the Long-Term",
    "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
    "url": "https://finnhub.io/api/news?id=a95154949db7d471b9a083bfee127effa64cb393b2fc8d47e2da3ff82b2e0e8a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770994203,
      "headline": "Why Eli Lilly (LLY) is a Top Momentum Stock for the Long-Term",
      "id": 139086540,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
      "url": "https://finnhub.io/api/news?id=a95154949db7d471b9a083bfee127effa64cb393b2fc8d47e2da3ff82b2e0e8a"
    }
  },
  {
    "ts": null,
    "headline": "CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens",
    "summary": "CRISPR Therapeutics highlights progress in clinical trials &amp; uptake of Casgevy gene therapy. Pipeline also advancing with promising data.",
    "url": "https://finnhub.io/api/news?id=73dc463cfd8f50b930bf3bcbaffd0c4ed0b9ca577b983f315833344df21c9bab",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770993949,
      "headline": "CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens",
      "id": 139095930,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/13/Crispr-Therapeutics.jpeg?width=2048&height=1536",
      "related": "LLY",
      "source": "Benzinga",
      "summary": "CRISPR Therapeutics highlights progress in clinical trials &amp; uptake of Casgevy gene therapy. Pipeline also advancing with promising data.",
      "url": "https://finnhub.io/api/news?id=73dc463cfd8f50b930bf3bcbaffd0c4ed0b9ca577b983f315833344df21c9bab"
    }
  },
  {
    "ts": null,
    "headline": "Elanco Announces Updates to Board of Directors",
    "summary": "Elanco Animal Health Incorporated (NYSE: ELAN) today announced updates to its Board of Directors. R. David Hoover and Deborah Kochevar will not stand for re-election at the conclusion of their terms at the 2026 Annual Meeting of Shareholders in May.",
    "url": "https://finnhub.io/api/news?id=fd7f662639b4dd3a12f0f112453043e5e5bc9061640a3cb9bc5c3a8354ebd761",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770992640,
      "headline": "Elanco Announces Updates to Board of Directors",
      "id": 139084997,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Elanco Animal Health Incorporated (NYSE: ELAN) today announced updates to its Board of Directors. R. David Hoover and Deborah Kochevar will not stand for re-election at the conclusion of their terms at the 2026 Annual Meeting of Shareholders in May.",
      "url": "https://finnhub.io/api/news?id=fd7f662639b4dd3a12f0f112453043e5e5bc9061640a3cb9bc5c3a8354ebd761"
    }
  },
  {
    "ts": null,
    "headline": "Novocure’s stock rises 37% on FDA clearance of pancreatic cancer treatment device",
    "summary": "Novocure’s Optune Pax delivers electric tumour treating fields (TTFields), targeting the electrical properties of cancer cells to thwart their survival and division.",
    "url": "https://finnhub.io/api/news?id=1f0772d25e2e20b806cf53b5a8bf2deb1f687b9ac9d59ac7f161a28e309453f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770986534,
      "headline": "Novocure’s stock rises 37% on FDA clearance of pancreatic cancer treatment device",
      "id": 139081163,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novocure’s Optune Pax delivers electric tumour treating fields (TTFields), targeting the electrical properties of cancer cells to thwart their survival and division.",
      "url": "https://finnhub.io/api/news?id=1f0772d25e2e20b806cf53b5a8bf2deb1f687b9ac9d59ac7f161a28e309453f4"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Expands Beyond GLP 1 With Cell And Genetic Therapies",
    "summary": "Eli Lilly (NYSE:LLY) announced an agreement to acquire Orna Therapeutics for up to $2.4b, adding circular RNA and in vivo CAR T technology to its drug development toolkit. The company also expanded its partnership with Innovent Biologics to work on new immunology and oncology treatments. These moves push Lilly further into cell and genetic therapies beyond its established diabetes and obesity drug portfolio. Eli Lilly enters this set of deals with a market profile shaped by a very large 3...",
    "url": "https://finnhub.io/api/news?id=3e439685b686240219f33bbec76e2db6cc28d5bf4431d59c5c444cc4fe5ec3c3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770984832,
      "headline": "Eli Lilly Expands Beyond GLP 1 With Cell And Genetic Therapies",
      "id": 139081164,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE:LLY) announced an agreement to acquire Orna Therapeutics for up to $2.4b, adding circular RNA and in vivo CAR T technology to its drug development toolkit. The company also expanded its partnership with Innovent Biologics to work on new immunology and oncology treatments. These moves push Lilly further into cell and genetic therapies beyond its established diabetes and obesity drug portfolio. Eli Lilly enters this set of deals with a market profile shaped by a very large 3...",
      "url": "https://finnhub.io/api/news?id=3e439685b686240219f33bbec76e2db6cc28d5bf4431d59c5c444cc4fe5ec3c3"
    }
  },
  {
    "ts": null,
    "headline": "Analysis-US could take action including fines against Hims after brief Wegovy copy launch",
    "summary": "WASHINGTON, Feb 13 (Reuters) - The Trump administration could take action including an injunction or fines against online telehealth company Hims for intending to sell a compounded version of Novo Nordisk's Wegovy weight-loss pill, though its legal options may be curbed by Hims' quick retreat, ‌attorneys and other experts told Reuters. Hims and Hers Health last week said it would offer a much cheaper $49 version of Novo Nordisk's Wegovy weight-loss pill, before ‌backing off the plan after the F",
    "url": "https://finnhub.io/api/news?id=ee434b59658dd6d832eba02a8f223525e5b4857587969170a7144144da1215ec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770981711,
      "headline": "Analysis-US could take action including fines against Hims after brief Wegovy copy launch",
      "id": 139079719,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "WASHINGTON, Feb 13 (Reuters) - The Trump administration could take action including an injunction or fines against online telehealth company Hims for intending to sell a compounded version of Novo Nordisk's Wegovy weight-loss pill, though its legal options may be curbed by Hims' quick retreat, ‌attorneys and other experts told Reuters. Hims and Hers Health last week said it would offer a much cheaper $49 version of Novo Nordisk's Wegovy weight-loss pill, before ‌backing off the plan after the F",
      "url": "https://finnhub.io/api/news?id=ee434b59658dd6d832eba02a8f223525e5b4857587969170a7144144da1215ec"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics: Buyers Are Quietly Accumulating On Its Obesity Drugs Launch Potential",
    "summary": "Viking Therapeutics, Inc. leverages manufacturing deals and commercial readiness to target $1.4B in revenue by 2030. Find out why VKTX stock is a buy.",
    "url": "https://finnhub.io/api/news?id=92e6492e1ba3be5783f6e4dc9556cf9e9069da142f93a4e21db7b04e53c566e1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770971700,
      "headline": "Viking Therapeutics: Buyers Are Quietly Accumulating On Its Obesity Drugs Launch Potential",
      "id": 139080474,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2213567500/image_2213567500.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Viking Therapeutics, Inc. leverages manufacturing deals and commercial readiness to target $1.4B in revenue by 2030. Find out why VKTX stock is a buy.",
      "url": "https://finnhub.io/api/news?id=92e6492e1ba3be5783f6e4dc9556cf9e9069da142f93a4e21db7b04e53c566e1"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Builds $1.5 Billion Inventory Of Experimental Weight-Loss Pill As FDA Decision Looms",
    "summary": "Eli Lilly and Company (NYSE: LLY) has stockpiled $1.5 billion worth of inventory of its experimental oral weight-loss drug, orforglipron, according to a regulatory filing on Thursday.",
    "url": "https://finnhub.io/api/news?id=afd07bc3962bd17af0e18cc9d3ba30022ac09cb4af61e73a5e3195f56504e498",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770964584,
      "headline": "Eli Lilly Builds $1.5 Billion Inventory Of Experimental Weight-Loss Pill As FDA Decision Looms",
      "id": 139081032,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/13/Los-Angeles--California---July-7-2025-El.jpeg?width=2048&height=1536",
      "related": "LLY",
      "source": "Benzinga",
      "summary": "Eli Lilly and Company (NYSE: LLY) has stockpiled $1.5 billion worth of inventory of its experimental oral weight-loss drug, orforglipron, according to a regulatory filing on Thursday.",
      "url": "https://finnhub.io/api/news?id=afd07bc3962bd17af0e18cc9d3ba30022ac09cb4af61e73a5e3195f56504e498"
    }
  },
  {
    "ts": null,
    "headline": "Prices, pipelines and patent cliffs: Inside pharma's big reset",
    "summary": "The new year is shaping up to be a defining year following a dramatic 2025, and one where the impact from last year's developments will crystallize.",
    "url": "https://finnhub.io/api/news?id=df96f791cb216e901bf4bc9085f5f034a80bf7fb4792e673d57c7ebe196d4cb9",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770963193,
      "headline": "Prices, pipelines and patent cliffs: Inside pharma's big reset",
      "id": 139085999,
      "image": "https://image.cnbcfm.com/api/v1/image/108204641-1758911651043-gettyimages-2237192235-nazir-notitle250926_np0Hd.jpeg?v=1758911691&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "The new year is shaping up to be a defining year following a dramatic 2025, and one where the impact from last year's developments will crystallize. ",
      "url": "https://finnhub.io/api/news?id=df96f791cb216e901bf4bc9085f5f034a80bf7fb4792e673d57c7ebe196d4cb9"
    }
  }
]